PROVISIONAL TECHNICAL EVALUATION REPORT FOR T NO 121-1 (COVID Medicines)								
s.no	Firm Name	Item Code	Item Name	Item Remarks	Status			
1	Akums Drugs & Pharmaceuticals Limited	Firm Remarks: May be considered						
		3456.07	Posaconazole Tablets 100mg		May be considered			
2	Bajaj Healthcare Limited	Firm Remarks: May be considered						
		3456.07	Posaconazole Tablets 100mg		May be considered			
3	LYKA LABS LIMITED	Firm Remarks: May be considered						
		1202.1	Amphotericin B Injection IP 50 mg in vial (Liposomal)		May be considered			
4	MEDISKY PHARMACEUTICALS	Firm Remarks: May be considered						
		3456.07	Posaconazole Tablets 100mg		May be considered			
5	MSN Laboratories Ltd	Firm Remarks: May be considered						
		3456.08	Posaconazole Inj 300mg		May be considered			
		3456.07	Posaconazole Tablets 100mg		May be considered			
6	Mylan Laboratories Limited	Firm Remarks: The Firm May not be considered , the firm submitted Loan License in Form-28A (as S.No: 02(a)(iii) of tender document condition), not submitted Processing Fee and Mandate form in prescribed format (submitted without bank seal).						
		3456.02	Remdesivir 100mg Inj (lyophilized)	Firm has submitted loan license product license in Form-28A	May not be considered			

S.NO	Firm Name	Item Code	Item Name	Item Remarks	Status		
7	Mylan Pharamaceuticals Pvt Ltd	Firm Remarks: May be considered after submission of Processing Fee					
		1202.1	Amphotericin B Injection IP 50 mg in vial (Liposomal)		May be considered		
8	NATCO PHARMA LTD	Firm Remarks: May be considered after submission of (1) Non Conviction certificate for Form-28 (2) Board resolution copy of Sri Vastava, Vicepresident.					
		1202.1	Amphotericin B Injection IP 50 mg in vial (Liposomal)		May be considered		
		3456.08	Posaconazole Inj 300mg		May be considered		

Note: All the bidders are here by requested to verify the Provisional Technical Evaluation Report and submit their supporting documents on or before 10.00.AM on 21.10.2021 to the email id: tenders.apmsidc@gmail.com with Subject: Reply to T No 121-1(COVID MED) TEC Report.